La diabetes y la HTA son los factores de riesgo cardiovascular hallados con más frecuencia en los ancianos y los que le confieren un mayor riesgo de enfermedad. Las peculiaridades del terreno sobre el que asienta la enfermedad (el paciente anciano), la frecuente comorbilidad y la peculiaridad de los objetivos terapéuticos propios de estos pacientes (más centrados en la preservación de la autonomía funcional que en la prolongación de la expectativa de vida) plantean una serie de consideraciones diagnósticas y terapéuticas. Estas consideraciones abarcan desde el propio significado pronóstico de la nefropatía hasta la indicación de tratamiento y objetivo de presión arterial del tratamiento hipotensor, pasando por la dificultad diagnóstica en función de las múltiples causas concurrentes que conducen a la nefropatía en las personas mayores, y sus manifestaciones clínicas o la ausencia de ensayos clínicos específicamente diseñados para evaluar el efecto de los fármacos en este grupo de población.
Palabras clave
Anciano
Nefropatía diabética
Hipertensión arterial
Tratamiento
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
P. Aranda, J.R. Banegas, R. Barajas, M. Luque, J.L. Rodicio.
Diagnosis and therapeutic management of hypercholesterolemic Spanish hypertensives.
J Hypertens, (1999), 17 pp. S192-S193
[2.]
A.J. Sinclair, R. Gadsby, S. Penfold, S.M.C. Croxon, A.J. Bayer.
Prevalence of diabetes in care home residents.
Diabetes Care, (2001), 24 pp. 1066-1068
[3.]
J. Manzarbeitia Arambarri.
Complicaciones y comorbilidad.
El anciano con diabetes. Sociedad Española de Endocrinología y Nutrición, Sociedad Española de Medicina Geriátrica, (2002),
[4.]
R.O. Estacio, J.G. Regensteiner, E.E. Wolfel, B. Jeffers, M. Dickenson, R.W. Schrier.
The association between diabetic complications and exercise capacity in NIDDM patients.
Diabetes Care, (1998), 21 pp. 291-295
[5.]
L. Rodríguez-Mañas.
El anciano con diabetes. Sociedad Española de Endocrinología y Nutrición.
Sociedad Española de Medicina Geriátrica, (2002),
[6.]
UKPDS Group.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38).
BMJ, (1998), 317 pp. 703-713
[7.]
A.H. Barnett.
Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
Acta Diabetol, (2005), 42 pp. S42-S49
[8.]
R. Boger, E. Schwedhelm, R. Maas, S. Quispe-Bravo, C. Skamira.
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Vasc Med, (2005), 10 pp. S97-102
[9.]
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). National High Blood Pressure Educations Program 2005.
[10.]
2003 European Society of Hypertension-European.
Society of Cardiology guidelines for the management of arterial hypertension.
J Hypertens, (2003), 21 pp. 1011-1053
[11.]
B. Williams, N.R. Poulter, M.J. Brown, M. Davis, G.T. McInnes, J.F. Potter.
BHS Guidelines Working Party, for the British Hypertension Society. British Hypertension Society Guidelines for hypertension management 2004 (BHS-IV): summary.
BMJ, (2004), 328 pp. 634-640
[12.]
A.J. Sinclair, P.V.M. Cromme, L. Rodríguez-Mañas, P. Fasching, M. Muggeo, C. Hader.
for the European Diabetes Working Party for Older People European Union Geriatric Medicine Society.
Clinical Guidelines for type 2 Diabetes Mellitus, (2004),
[13.]
R. Peters, N. Beckett, M. Nunes, A. Fletcher, F. Forette, C. Bulpitt.
A substudy protocol of the hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVETCOG): an ongoing randomised, double-blind, placebo-controlled trial.
Drugs Aging, (2006), 23 pp. 83-92
[14.]
Guidelines for the management and care of diabetes in the elderly. Australian Diabetes Educators Association; 2003.
[15.]
C. Qiu, B. Winblad, L. Fratiglioni.
The age-dependent relation of blood pressure to cognitive function and dementia.
Lancet Neurol, (2005), 4 pp. 487-499
[16.]
V.W. Chris, F.G. Schellevis.
Comorbidity and guidelines: conflicting interests.
Lancet, (2006), 367 pp. 550-551
[17.]
T. Ekbom, E. Linjer, T. Hedner, J. Lanke, U. De Faire, P.O. Wester, et al.
Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Blood Press, (2004), 13 pp. 137-141
[18.]
J.P. Casas, W. Chua, S. Loukogeorgakis, P. Vallance, L. Smeeth, A.D. Hingorani, et al.
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.
Lancet, (2005), 366 pp. 2026-2033
[19.]
A.H. Barnett, S.C. Bain, P. Bouter, B. Karlberg, S. Madsbad, J. Jervell, et al.
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
N Eng J Med, (2004), 351 pp. 1952-1961
[20.]
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.
Heart Outcomes Prevention Evaluation Study Investigators.
Lancet, (2000), 355 pp. 253-259
[21.]
N.H. Andersen, P.L. Poulsen, S.T. Knudsen, S.H. Poulsen, H. Eiskjaer, K.W. Hansen.
Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.
Diabetes Care, (2005), 28 pp. 273-277
[22.]
P.R. Kowey, T.Z. Dickson, Z. Zhang, F. Shahinfar, B.M. Brenner.
Losartan and end-organ protection—lessons from the RENAAL study.
Clin Cardiol, (2005), 28 pp. 136-142
[23.]
K.F. Croom, M.P. Curran, K.L. Goa, C.M. Perry.
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Drugs, (2004), 64 pp. 999-1028
[24.]
G. Viberti, N.M. Wheeldon.
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
Circulation, (2002), 106 pp. 672-678
[25.]
J.A. Spertus, E. Peterson, J.S. Rumsfield, P.G. Jones, C. Decker, H. Krumholz.
The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER) evaluating the impact of myocardial infarction on patient outcomes.
Am Heart J, (2006), 151 pp. 589-597
[26.]
J. Rippin, S.C. Bain, A.H. Barnett.
Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.
J Diabet Compl, (2002), 16 pp. 195-200
[27.]
G. Mancia.
The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction.
Acta Diabetol, (2005), 42 pp. S17-S25
[28.]
G.F. Strippoli, M. Craig, J.C. Craig.
Antihypertensive agents for preventing diabetic kidney disease.
Cochrane Database Syst Rev, (2005), 19
[29.]
L. Rodríguez Mañas, M. Castro.
Terapia farmacológica en medicina geriátrica.
Fundamentos de farmacología básica y clínica, Editorial Universitaria Ramón Areces, (2005),
¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?